Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019629 · ClinicalTrials.gov registry record
Fabry Screening Study
A clinical trial of Fabry Disease, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 2,724
- Enrollment target
- 1
- Study location
NCT01019629: Completed study of Fabry Disease, sponsored by Baylor Research Institute.
NCT01019629 is a study of Fabry Disease that has completed, run by Baylor Research Institute. The registered enrollment target is 2,724 participants, above the 458-participant average among 32 other Fabry Disease trials with a reported enrollment target (495% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01019629, a study of Fabry Disease, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 2,724 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if patients with a deficiency of alpha-galactosidase A are at-risk for cardiac complications that commonly occur in the general population
Primary Outcome
Collect blood and urine sample one time only for analysis
Conditions Studied
Study Locations (1)
Texas
- Baylor Institute of Metabolic Disease - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,724 participants |
| Start Date | 2009-01-29 |
| Est. Completion | 2017-12-07 |
What the finished NCT01019629 record still lists
NCT01019629 is an observational study that tracks outcomes without assigning an intervention. Its 2,724 participants enrollment target places it among the larger protocols in the corpus, above the 458-participant average among 32 other Fabry Disease trials with a reported enrollment target (495% higher).
The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01019629 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01019629 about?
NCT01019629 is a clinical study titled "Fabry Screening Study". To determine if patients with a deficiency of alpha-galactosidase A are at-risk for cardiac complications that commonly occur in the general population
What is the current status of trial NCT01019629?
This trial is currently completed. The enrollment target is 2,724 participants. The study started on 2009-01-29. Estimated completion is 2017-12-07.
What conditions does trial NCT01019629 study?
This clinical trial studies the following conditions: Fabry Disease.
Who is sponsoring clinical trial NCT01019629?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01019629 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01019629's enrollment target sits among peer trials
2,724 3rd of 32 higher than 30 of 32 other Fabry Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fabry Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
-
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
RECRUITING
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RECRUITING · Phase 3
-
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RECRUITING · Phase 2
-
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
RECRUITING
-
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI